BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR 15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longe

Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

and VANCOUVER, British Columbia, April 17, 2023- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"

or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is presenting

positive clinical data from its lead product candidate, Bria-IMT , summarized in four poster sessions during the 2023 American

Association for Cancer Research (AACR) Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando,

data highlights the potential clinical value of the Bria-MT regimen in patients with advanced metastatic breast cancer after receiving

multiple prior therapies," said Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate

Professor of Clinical Medicine, Principal Clinical Investigator, and co-author of the study of Bria-IMT in combination with PD-1

inhibitors pembrolizumab and retifanlimab. "These results are promising and the fact that patients have had a great quality of

life thus far is remarkable. We are hopeful that this novel immunotherapy proves to be an effective therapy for our patients."

clinical findings continue to confirm our approach for our upcoming pivotal trial of Bria-IMT combination regimen," commented

Dr. William V. Williams, BriaCell's President and CEO. "With over 40,000 annual deaths in the U.S. alone, advanced metastatic

breast cancer remains an unmet medical need. Patients who have only months to live tend to avoid current therapies that are proven ineffective

and are associated with excessive toxicities. BriaCell's regimen has shown robust clinical efficacy, better than expected survival

outcomes, and an excellent safety profile in this very difficult to treat patient cohort. We are seeing benefits in patients who failed

other treatments and/or cannot tolerate the harsh side effects of other therapies."

posters are summarized below and linked here: https://briacell.com/scientific-publications/.

1 - Title: Whole cell antigen presenting immune stimulating cells (Bria-IMT ) for the treatment of metastatic breast cancer

Abstract Presentation Number: CT143

Progression Free Survival and Clinical Benefit

Free Survival (PFS) is the length of time during which a patient's cancer does not get worse and is used as a key survival and

efficacy measurement. PFS benefit was observed in BriaCell's combination regimen (with PD-1 inhibitor pembrolizumab (n=11) or retifanlimab

(n=20)), as measured by PFS difference from a patient's previous therapy (prior to enrolment in BriaCell's study). Most patients'

PFS values were similar or higher than those of their prior regimen, a positive finding that suggests better tolerability, clinical effectiveness,

and survival time. Patients treated with Bria-IMT remained on treatment for a longer period of time than expected. BriaCell's

patient cohort would have typically experienced shorter time on therapy with each subsequent line of treatment, given their advanced

18 patients recruited since the study reopened in 2021, 15 remain alive. This compares extremely well with overall survival of 6.7-9.8

months in other similar studies.1

data suggest a survival benefit in this group of difficult to treat patients who had failed multiple prior treatments and who had a typical

life expectancy of 6 months or less.

vs. Non-Anergic Patients:

cells, which can actively weaken the immune system, thus avoid being detected by the patient's immune system, allowing them to

grow and spread. This is a particularly pronounced problem in anergic patients (those unable to develop an immune response) who have

very weak immune systems. Delayed-type hypersensitivity (DTH) test was used to determine immune responses to Bria-IMT as a measure

of immune system activation/boost in patients treated with BriaCell's combination regimen.

out of 27 (56%) evaluable patients from BriaCell's combination study were anergic (i.e. weak immune systems). Following the treatment

with the Bria-IMT combination regimen, 70% of anergic patients and 89% of non-anergic patients showed immune system activation/boost.

Bria-IMT regimen activated/boosted the immune system and produced clinical benefit in both non-anergic and anergic patients with

more (i.e. double) clinical benefit in patients who developed an immune response to Bria-IMT .

observations are particularly meaningful for anergic patients with weakened immune systems who have failed to respond to multiple prior

Receptor Positive (HR+) Patients: Survival and clinical benefits were observed across multiple subtypes of advanced metastatic breast

cancer patients, especially in patients with hormone receptor positive (HR+) cancer, a very large segment of the patient population.

No immunotherapies have been shown to work in this group of patients. 8 out of 17 HR+ patients experienced progression-free

survival benefits in the BriaCell combination study.

Kazmi 2020; Adams 2022, O'Shaughnessy 2022.

positive data is expected as current patients continue to remain in our study, and new patients are being enrolled.

2 - Title: Engineering semi-allogeneic whole cancer vaccines with enhanced immunogenicity for the treatment of advanced solid tumors

Abstract Number: 685

has developed Bria-OTS2.0 or Bria-APTC, the next generation (enhanced version) of Bria-OTS , BriaCell's off-the-shelf personalized

immunotherapy for advanced metastatic breast cancer. It expresses other immune activating cytokine molecules in addition to its immune

boosting granulocyte-macrophage colony-stimulating factor (GM-CSF). As expected, Bria-OTS2.0 was significantly more effective than Bria-OTS

in activating na ve T-cells, potentially suggesting faster acting mechanisms of action and better potency. Bria-OTS2.0 may deliver

significant clinical efficacy and survival benefits in advanced metastatic breast cancer for the following reasons:

mechanisms of action to achieve strong immune response and clinical activity: The unique mechanism of action allows both direct activation

of T-cells, and indirect activation (i.e., by producing immune activating factors) of the immune cells for a more potent and faster acting

anti-tumor activity.

continues to develop Bria-OTS2.0 to enhance the potency of the initial version of Bria-OTS which is planned to be used in its

upcoming phase I/IIa clinical study. The pre-made design should allow fast and cost-effective treatment of patients within days following

a simple, rapid, and inexpensive HLA typing saliva test.

following two posters were presented in a collaboration led by a team from Creatv MicroTech, Inc., an oncology diagnostic company. Both

posters show potential easy to conduct diagnostic tests to predict clinical benefit in patients with advanced metastatic breast cancer.

3 - Title: Tumor macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid

progression and death

Abstract Number: 2310

4 - Title: Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast

Abstract Number: 304

BriaCell Therapeutics Corp.

is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information

is available at https://briacell.com/.

press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,

other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will," "would," or the negative of these words or other similar expressions, although not all forward-looking

statements contain these words. Examples of forward-looking statements in this news release include statements about: (i) BriaCell's

participation at the American Association for Cancer Research (AACR) 2023 Annual Meeting; (ii) the potential clinical value of Bria-IMT

(iii) the clinical efficacy, survival rates and safety profile associated with BriaCell's regimen; (iv) the potential content of

posters presented at AACR with respect to refreshed survival outcome updates, new patient data related to tolerability, clinical effectiveness

and survival time, among other things, and potential late-breaking discoveries; (v) the ability of Bria-OTS2.0 to be faster acting and

have better potency than Bria-OTS (vi) the ability of Bria-OTS2.0 to deliver significant clinical efficacy and survival benefits;

and (vii) the continued development of Bria-OTS2.0. Forward-looking statements are based on BriaCell's current expectations and

are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements

are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described

more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and

Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks

and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities

and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on

EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell

Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)

accepts responsibility for the adequacy or accuracy of this release.

Director of Public Relations